1. Faris RF, Flather M, Purcell H, et al. Diuretics for heart failure. Cochrane Database Syst Rev. 2012;(2):CD003838.
2. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736-1754.
3. Lax D, Bhatt RD, Klewer SE, et al. Are all ventricular septal defects created equal? J Am Soc Echocardiogr. 2010;23(7):791.e5-791.e7.
4. Scully BB, Morales DL, Zafar F, et al. Current expectations for surgical repair of isolated ventricular septal defects. Ann Thorac Surg. 2010;89(2): 544-549.
5. Yang L, Tai BC, Khin LW, et al. A systematic review on the efficacy and safety of transcatheter device closure of ventricular septal defects (VSD). J Interv Cardiol. 2014;27(3):260-272.
6. Yin S, Zhu D, Lin K, et al. Perventricular device closure of congenital ventricular septal defects. J Card Surg. 2014;29(3):390-400.
7. American Academy of Pediatrics Committee on Infectious Diseases; American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics. 2014;134(2):415-420.
8. Menting ME, Cuypers JA, Opić P, et al. The unnatural history of the ventricular septal defect: outcome up to 40 years after surgical closure. J Am Coll Cardiol. 2015;65(18):1941-1951.